Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SB209509: Started a Phase I U.K. trial in 18 healthy volunteers, of whom 12 will receive drug and 6 placebo. The rising dose tolerance study will look at oral d

Vanguard Medica (Guilford, U.K.)
Product: SB209509, 5HT1D

Read the full 74 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE